Molnupiravir (EIDD-2801) CAS 2349386-89-4 COVID-19 API Zoo
Kev Lag Luam Kev Lag Luam Molnupiravir thiab Cov Neeg Nruab Nrab cuam tshuam nrog Cov Khoom Zoo
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Tshuaj npe | Molnupiravir (EIDD-2801) |
| Synonyms | MK-4482;β-D-N4-Hydroxycytidine-5′-isopropyl ester;((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2 -yl)methyl isobutyrate |
| CAS Nr | 2349386-89-4 |
| CAT Number | RF-API 97 |
| Tshuag xwm txheej | Nyob rau hauv Tshuag, ntau lawm Scale nce mus txog pua pua ntawm Kilograms |
| Molecular Formula | C13H19N3O7 |
| Molecular Luj | 329.31 Nws |
| Solubility | Soluble hauv DMSO |
| Hom | Ruifu Tshuaj |
| Yam khoom | Specifications |
| Qhov tshwm sim | Dawb rau Off-White Powder |
| Identification IR | Sample Spectrum sib raug raws li tus qauv siv |
| Kev txheeb xyuas HPLC | Lub sijhawm khaws cia ntawm lub ncov loj ntawm cov qauv kev daws teeb meem sib raug rau cov qauv kev daws teeb meem |
| Yam khoom muaj feem | |
| impurity A | ≤ 0.15% |
| Impurity B | ≤ 0.15% |
| Tej yam tsis meej tsis meej | ≤ 0.15% |
| Tag nrho Unspecified Impurities | ≤ 0.30% |
| Tag nrho cov impurities | ≤0.50% |
| Residual Solvents | |
| N-Heptane | ≤5000ppm |
| Ethanol | ≤5000ppm |
| Isopropyl Acetate | ≤5000ppm |
| Cov tshuaj acetonitrile | ≤410ppm |
| Methylene Dichloride | ≤600ppm |
| Acetone | ≤5000ppm |
| Isopropanol | ≤5000ppm |
| Cov ntsiab lus dej (KF) | ≤0.50% |
| Residue ntawm Ignition | ≤0.10% |
| Kev hloov kho qhov muag | -7.5 ° txog -9.5 ° C = 0.5, Methanol |
| Hnyav Hlau | ≤10ppm |
| Purity / Analysis Method | ≥99.5% (230nm) |
| Assay / Analysis Method | 98.0% ~ 102.0% (HPLC ntawm qhuav hauv paus) |
| Txee lub neej | 24 Lub Hlis |
| Test Standard | Enterprise Standard |
| Kev siv | API, Molnupiravir (EIDD-2801) COVID-19 Inhibitor |
Pob: Lub raj mis, Aluminium ntawv ci hnab, Cardboard nruas, 25kg / Nruas, los yog raws li tus neeg yuav tsum tau muaj.
Cia txias:Khaws rau hauv cov thawv ntim khoom ntawm qhov chaw txias thiab qhuav;Tiv thaiv los ntawm lub teeb, noo noo thiab kab tsuag.
Molnupiravir (EIDD-2801, MK-4482) yog ib qho kev hais lus bioavailable prodrug ntawm ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) nrog broad-spectrum antiviral kev ua haujlwm tawm tsam SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19.Molnupiravir yog muag raws li lub npe Lagevrio thiab feem ntau yog emorivir.Molnupiravir tau pom tias txhim kho pulmonary muaj nuj nqi, txo lub cev hnyav thiab txo tus nqi ntawm tus kab mob hauv lub ntsws.Ntxiv nrog rau kev ua haujlwm tiv thaiv tus kabmob coronaviruses, Molnupiravir, hauv kev tshawb fawb hauv chav kuaj, tau qhia txog kev ua haujlwm tawm tsam raws caij nyoog thiab noog khaub thuas, tus kab mob ua pa syncytial, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, thiab Eastern equine encephalitis virus.Molnupiravir yog thawj zaug tsim los kho tus mob khaub thuas ntawm Emory University los ntawm lub tsev kawm ntawv lub tuam txhab tshuaj innovation, Drug Innovation Ventures ntawm Emory (DRIVE), tab sis tau tshaj tawm tias tau tso tseg rau kev txhawj xeeb txog kev hloov pauv.Tom qab ntawd nws tau txais los ntawm Miami-based tuam txhab Ridgeback Biotherapeutics, uas tom qab tau koom tes nrog Merck & Co. los tsim cov tshuaj ntxiv.Molnupiravir tau pom zoo siv kho mob hauv tebchaws United Kingdom thaum lub Kaum Ib Hlis 2021.
